Overheard: 2024 Houston Innovation Awards finalists share top advice for fellow founders

weighing in

Clockwise from top: Lori-Lee Elliot, Anwar Sadek, Mimi Healy, Ram Prasad, Tatiana Fofanova, Prabhdeep Sekhon, Raisha Smith, and Mitra Miller.

There's a great deal of advice swirling around the world today about how to find success business. Why not take it from mentors and founders with a proven track record, like the finalists for this year's Houston Innovation Awards?

From how to grow your customer base to tips on combating funding gaps and making room for yourself at the table, they shared priceless tokens of advice in their applications for the 2024 awards.

Here's what some of the leading founders and supporters in Houston's Innovation community had to say.

"Just because you don't look like everyone else in there room, or aren't offered a seat at the table, doesn't mean you don't deserve to be there. If anything, it means the world needs you there more."

–Lori-Lee Elliott, Co-Founder and CEO of Dauntless XR, female-founded business finalist

"Don’t shy away from seeking non-traditional forms of funding like grants and non-dilutive capital, especially if VC funding seems out of reach. Surround yourself with mentors who understand your challenges, and be intentional about expanding your network to build strategic connections. Above all, stay confident in your vision, use every opportunity to learn, and never hesitate to give back by helping othersalong the way. Your success not only opens doors for you but for future generations of minority founders."

-Anwar Sadek, CORROLYTICS CEO and co-founder, minority-founded business finalist

"Being an entrepreneur is fun and hard and exhilarating and frustrating and simple and complicated and joyful and exhausting and worth it. Make a plan so you can change your plan because the market changed, because the competition grew, because your data showed something different than what you expected, because you hired or lost a team member, because you raised more money, because you didn't raise enough money. Take the time to make the plan and think about all the ways it could change, so that whenit does, it is not the first time you thought about what to do because it will be too late."

–Mimi Healy, CEO of StimulusBio, mentor of the Year finalist

"My go-to advice for entrepreneurs is to prioritize their health while building their business. It’s easy to get caught up in the hustle, but long-term success comes from sustaining your physical and mental well-being. Entrepreneurs need to be at their best to make good decisions, lead effectively, and navigate challenges, so focusing on health isn’t just a luxury—it’s essential.Another key habit I always recommend is setting aside at least one hour a day to actively find new customers. Customer acquisition is the lifeblood of any business, and dedicating this time daily can help you build momentum, create relationships, and discover new opportunities that may have been overlooked."

–Ram Prasad, CEO of Delence, minority-owned business finalist

"Learn to sit on the other side of the table and think about things from the other person's perspective. When seeking funding, this means thinking about the investor's point of view. When selling, it means thinking about the customer's POV. How are you—the founder—helping them win?"

--Mitra Miller, Vice President of Houston Angel Network, mentor of the Year finalist

"Leverage the strength of your community. And as a founder, you are the secret sauce, not the imposter. Building a network of supportive peers and mentors who understand your unique challenges can be a game-changer. At EveryDopeGirl, we've seen how powerful it is when minority founders come together to share resources, insights, and encouragement. Don't hesitate to seek out and participate in events that foster these connections. Remember, your journey is not just about overcoming obstacles, but also about celebrating your successes and the unique perspectives you bring to the table."

-Raisha Smith, founder of EveryDopeGirl, female-founded business finalist

""Focus on your strengths rather than getting caught up in perceived gaps or doubts. Embrace the diversity in your team, just as we’ve done at Gold H2, where 50 percent of our team is female and 80 percent are visible minorities. Diversity brings strength ... Trust yourself, and don’t be afraid to shape your journey in both your career and personal life."

–Prabhdeep Sekhon, CEO of Gold H2, minority-owned business finalist

"Surround yourself with two types of people: the lovers and the fighters. First, surround yourself with people that love you and believe in your vision–they'll be the ones who pick you up when your spirit takes a beating and you feel like giving up. Second, surround yourself with those who you can categorically trust to fight to the bitter end-when life happens, they'll be the ones running the ship andkeeping the dream alive while you sort things out. These will almost never be the same people, so you have to find both."

-Tatiana Fofanova, CEO of Koda Health, female-founded business finalist

From Your Site Articles
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings